# US 2025/0222136 A1 · Gene editing system for treating usher syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0222136 A1
- Document ID: US20250222136A1
- Status: Published application
- Kind: A1
- Application number: 18/853,023
- Filed: 2023-03-30
- Published: 2025-07-10
- Earliest claimed: 2022-03-30
- Applicants: GenKOre, Inc.
- Inventors: Yong Sam KIM; Do Yon KIM
- Web page: https://patentgrep.com/patent/US20250222136A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/102: {Mutagenizing nucleic acids}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12N 15/907: {in mammalian cells}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a gene editing system for treating Usher syndrome, to a disease treatment method using same, and the like, wherein by using the gene editing system of the present invention, an exon 13 region mutated in the Usherin (USH2A) gene is deleted with high efficiency, thereby treating type 2 Usher syndrome effectively. In addition, the gene editing system of the present invention comprises a miniaturized Cas12f1 protein-based endonuclease and an engineered guide RNA having a shorter length and improved indel efficiency, and a carrier having a limited packaging size, such as adeno-associated virus (AAV), can also be used, and therefore, in vivo or intracellular delivery efficiency can also be maximized.

## Claims

### Claim 1

A system for editing a USH2A gene, comprising:
an endonuclease comprising a Cas12f1 molecule or a nucleic acid encoding the endonuclease;
a first guide RNA comprising a first guide sequence capable of hybridizing to a target sequence of contiguous 15 to 30 bp in length, wherein the target sequence is located in a region 5000 bp upstream of USH2A exon 13 and is adjacent to a protospacer-adjacent motif (PAM) sequence recognized by the Cas12f1 molecule, or a nucleic acid encoding the first guide RNA; and
a second guide RNA comprising a second guide sequence capable of hybridizing to a target sequence of contiguous 15 to 30 bp in length, wherein the target sequence is located in a region 14500 bp downstream of USH2A exon 13 and is adjacent to a PAM sequence recognized by the Cas12f1 molecule, or a nucleic acid encoding the second guide RNA.

### Claim 2 (depends on 1)

The system of claim 1, wherein the system induces deletion of exon 13 in the USH2A gene in a cell.

### Claim 3 (depends on 1)

The system of claim 1, wherein the system is for treatment of type 2A Usher syndrome.

### Claim 4 (depends on 1)

The system of claim 1, wherein the USH2A exon 13 comprises at least one mutation that causes Usher syndrome.

### Claim 5 (depends on 1)

The system of claim 1, wherein the target sequence located in a region 5000 bp upstream of USH2A exon 13 comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 49, and/or
the target sequence located in a region 14500 bp downstream of the USH2A exon 13 comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 50 to 79.

### Claim 6 (depends on 1)

The system of claim 1, wherein the first guide sequence comprises a sequence of contiguous 15 to 22 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 397 to 445, or a sequence that is different by 5 or fewer nucleotides from the contiguous nucleotide sequence, wherein thymine (T) in the contiguous nucleotide sequence is substituted with uracil (U), and/or
the second guide sequence comprises a sequence of contiguous 15 to 20 nucleotides in a nucleotide sequence selected from the group consisting of SEQ ID NOs: 446 to 475, or a sequence that is different by 5 or fewer nucleotides from the contiguous nucleotide sequence, wherein thymine (T) in the contiguous nucleotide sequence is substituted with uracil (U).

### Claim 7 (depends on 1)

The system of claim 1, wherein the first guide sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 80 to 128 and SEQ ID NOs: 159 to 164, and/or
the second guide sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 129 to 158 and SEQ ID NOs: 165 to 174.

### Claim 8 (depends on 1)

The system of claim 1, wherein the first or second guide RNA comprises a U-rich tail sequence linked to the 3′ end of the guide sequence, in which the U-rich tail is represented by 5′-(UmV)nUo-3′, wherein V is each independently A, C, or G; m and o are integers between 1 to 20; and n is an integer between 0 to 5.

### Claim 9 (depends on 1)

The system of claim 1, wherein the first or second guide RNA comprises an engineered scaffold region, and the engineered scaffold region comprises a nucleotide sequence having at least 50% sequence identity to a scaffold region of a wild-type Cas12f1 guide RNA sequence, in which the scaffold region sequentially comprises, from the 5′-end, a first stem-loop region, a second stem-loop region, a third stem-loop region, a fourth stem-loop region, and a tracrRNA-crRNA complementarity region, and comprises at least one modification selected from the group consisting of the following (1) to (4) with respect to the wild-type Cas12f1 guide RNA sequence:
(1) deletion of at least a part of the first stem-loop region;
(2) deletion of at least a part of the second stem-loop region;
(3) deletion of at least a part of the tracrRNA-crRNA complementarity region; and
(4) replacement of one or more uracil (U) residues with A, G, or C in three or more consecutive U residues when the consecutive U residues are present in the tracrRNA-crRNA complementarity region.

### Claim 10 (depends on 9)

The system of claim 9, wherein the wild-type Cas12f1 guide RNA comprises tracrRNA comprising the nucleotide sequence of SEQ ID NO: 175 and crRNA comprising the nucleotide sequence of SEQ ID NO: 176.

### Claim 11 (depends on 9)

The system of claim 9, wherein the engineered scaffold region comprises a sequence having at least 80% sequence identity to a sequence represented by Formula (I):
in Formula (I),
Xa comprises the nucleotide sequence of SEQ ID NO: 178 or a nucleotide sequence having the sequence of SEQ ID NO: 178 from which 1 to 20 nucleotides are deleted,
Xb1 comprises the nucleotide sequence of SEQ ID NO: 189 or a nucleotide sequence having the sequence of SEQ ID NO: 189 from which 1 to 13 nucleotides are deleted,
Xb2 comprises the nucleotide sequence of SEQ ID NO: 193 or a nucleotide sequence having the sequence of SEQ ID NO: 193 from which 1 to 14 nucleotides are deleted,
Xc1 comprises the nucleotide sequence of SEQ ID NO: 203 or a nucleotide sequence having the sequence of SEQ ID NO: 203 from which 1 to 28 nucleotides are deleted,
Xc2 comprises the nucleotide sequence of SEQ ID NO: 222 or a nucleotide sequence having the sequence of SEQ ID NO: 222 from which 1 to 27 nucleotides are deleted, and
Lk is a polynucleotide linker of 2 to 20 nucleotides in length or absent.

### Claim 12 (depends on 11)

The system of claim 11, wherein in a case where three or more consecutive uracil (U) residues are present in the Xc1 sequence, the Xc1 sequence comprises a modification in which at least one U residue thereof is replaced with A, G or C.

### Claim 13 (depends on 11)

The system of claim 11, wherein the deletion in the nucleotide sequence of Xa, the deletion in the nucleotide sequences of Xb1 and Xb2, and/or the deletion in the nucleotide sequences of Xc1 and Xc2 comprises deletion of one or more pairs of complementary nucleotides.

### Claim 14 (depends on 11)

The system of claim 11, wherein the sequence 5′-Xb1UUAGXb2-3′ in Formula (I) is selected from the group consisting of SEQ ID NOs: 198 to 202 and 5′-UUAG-3′.

### Claim 15 (depends on 11)

The system of claim 11, wherein the sequence 5′-Xc1-Lk-Xc2-3′ in Formula (I) is selected from the group consisting of SEQ ID NOs: 244 to 250 and 5′-Lk-3′.

### Claim 16 (depends on 9)

The system of claim 9, wherein the scaffold region comprises an engineered tracrRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 251 to 296 and/or
an engineered crRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 297 to 304.

### Claim 17 (depends on 1)

The system of claim 1, wherein the first or second guide RNA is a dual guide RNA or a single guide RNA.

### Claim 18 (depends on 1)

The system of claim 1, wherein the first or second guide RNA comprises a scaffold region sequence of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 313 to 350.

### Claim 19 (depends on 1)

The system of claim 1, wherein the Cas12f1 molecule comprises an amino acid sequence having at least 70% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 360 to 364 and SEQ ID NOs: 370 to 377.

### Claim 20 (depends on 1)

The system of claim 1, wherein the endonuclease forms a ribonucleoprotein (RNP) with the first guide RNA or the second guide RNA.

### Claim 21

A vector system, comprising at least one vector wherein the at least one vector comprises:
a first nucleic acid construct to which a nucleotide sequence encoding an endonuclease is operably linked, the endonuclease comprising a Cas12f1 molecule;
a second nucleic acid construct to which a nucleotide sequence encoding a first guide RNA is operably linked, the first guide RNA comprising a first guide sequence capable of hybridizing to a target sequence of contiguous 15 to 30 bp in length, wherein the target sequence is located in a region 5000 bp upstream of USH2A exon 13 and is adjacent to a protospacer-adjacent motif (PAM) sequence recognized by the Cas12f1 molecule; and
a third nucleic acid construct to which a nucleotide sequence encoding a second guide RNA is operably linked, the second guide RNA comprising a second guide sequence capable of hybridizing to a target sequence of contiguous 15 to 30 bp in length, wherein the target sequence is located in a region 14500 bp downstream of USH2A exon 13 and is adjacent to a PAM sequence recognized by the Cas12f1 molecule.

### Claim 22 (depends on 21)

The vector system of claim 21, wherein the vector system induces deletion of exon 13 in a USH2A gene in a cell.

### Claim 23 (depends on 21)

The vector system of claim 21, wherein the USH2A exon 13 comprises at least one mutation that causes Usher syndrome.

### Claim 24 (depends on 21)

The vector system of claim 21, wherein the nucleic acid constructs are contained in the same or different vectors.

### Claim 25 (depends on 21)

The vector system of claim 21, wherein the nucleic acid constructs are contained in one vector.

### Claim 26 (depends on 21)

The vector system of claim 21, wherein the target sequence located in a region 5000 bp upstream of USH2A exon 13 comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1 to 49, and/or
the target sequence located in a region 14500 bp downstream of USH2A exon 13 comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 50 to 79.

### Claim 27 (depends on 21)

The vector system of claim 21, wherein the first guide sequence comprises a sequence of contiguous 15 to 22 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 397 to 445, or a sequence that is different by 5 or fewer nucleotides in the contiguous nucleotide sequence, wherein thymine (T) in the contiguous nucleotide sequence is substituted with uracil (U), and/or
the second guide sequence comprises a sequence of contiguous 15 to 20 nucleotides in a nucleotide sequence selected from the group consisting of SEQ ID NOs: 446 to 475, or a sequence that is different by 5 or fewer nucleotides in the contiguous nucleotide sequence, wherein thymine (T) in the contiguous nucleotide sequence is substituted with uracil (U).

### Claim 28 (depends on 21)

The vector system of claim 21, wherein the first guide sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 80 to 128 and SEQ ID NOs: 159 to 164, and/or
the second guide sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 129 to 158 and SEQ ID NOs: 165 to 174.

### Claim 29 (depends on 21)

The vector system of claim 21, wherein the first or second guide RNA comprises a U-rich tail sequence linked to the 3′ end of the guide sequence, in which the U-rich tail is represented by 5′-(UmV)nUo-3′, wherein V is each independently A, C, or G; m and o are integers between 1 to 20; and n is an integer between 0 to 5.

### Claim 30 (depends on 21)

The vector system of claim 21, wherein the first or second guide RNA comprises an engineered scaffold region, wherein the engineered scaffold region comprises a nucleotide sequence having at least 50% sequence identity to a scaffold region of a wild-type Cas12f1 guide RNA sequence, which sequentially comprises, from the 5′-end, a first stem-loop region, a second stem-loop region, a third stem-loop region, a fourth stem-loop region and a tracrRNA-crRNA complementarity region, and comprises at least one modification selected from the group consisting of the following (1) to (4):
(1) deletion of at least a part of the first stem-loop region;
(2) deletion of at least a part of the second stem-loop region;
(3) deletion of at least a part of the tracrRNA-crRNA complementarity region; and
(4) replacement of one or more uracil (U) residues with A, G, or C in three or more consecutive U residues when the consecutive U residues are present in the tracrRNA-crRNA complementarity region.

### Claim 31 (depends on 30)

The vector system of claim 30, wherein the wild-type Cas12f1 guide RNA comprises tracrRNA comprising the nucleotide sequence of SEQ ID NO: 175 and crRNA comprising the nucleotide sequence of SEQ ID NO: 176.

### Claim 32 (depends on 30)

The vector system of claim 30, wherein the engineered scaffold region comprises a sequence having at least 80% sequence identity to a sequence represented by Formula (I):
in Formula (I),
Xa comprises the nucleotide sequence of SEQ ID NO: 178 or a nucleotide sequence having the sequence of SEQ ID NO: 178 from which 1 to 20 nucleotides are deleted,
Xb1 comprises the nucleotide sequence of SEQ ID NO: 189 or a nucleotide sequence having the sequence of SEQ ID NO: 189 from which 1 to 13 nucleotides are deleted,
Xb2 comprises the nucleotide sequence of SEQ ID NO: 193 or a nucleotide sequence having the sequence of SEQ ID NO: 193 from which 1 to 14 nucleotides are deleted,
Xc1 comprises the nucleotide sequence of SEQ ID NO: 203 or a nucleotide sequence having the sequence of SEQ ID NO: 203 from which 1 to 28 nucleotides are deleted,
Xc2 comprises the nucleotide sequence of SEQ ID NO: 222 or a nucleotide sequence having the sequence of SEQ ID NO: 222 from which 1 to 27 nucleotides are deleted, and
Lk is a polynucleotide linker of 2 to 20 nucleotides in length or absent.

### Claim 33 (depends on 32)

The vector system of claim 32, wherein in a case where three or more consecutive uracil (U) residues are present in the Xc1 sequence, the system comprises a modification in which at least one U residue thereof is replaced with A, G or C.

### Claim 34 (depends on 32)

The vector system of claim 32, wherein the deletion in the nucleotide sequence of Xa, the deletion in the nucleotide sequences of Xb1 and Xb2, and/or the deletion in the nucleotide sequences of Xc1 and Xc2 comprises deletion of one or more pairs of complementary nucleotides.

### Claim 35 (depends on 32)

The vector system of claim 32, wherein the sequence 5′-Xb1UUAGXb2-3′ in Formula (I) is selected from the group consisting of SEQ ID NOs: 198 to 202 and 5′-UUAG-3′.

### Claim 36 (depends on 32)

The vector system of claim 32, wherein the sequence 5′-Xc1-Lk-Xc2-3′ in Formula (I) is selected from the group consisting of SEQ ID NOs: 244 to 250 and 5′-Lk-3′.

### Claim 37 (depends on 32)

The vector system of claim 32, wherein the Lk comprises a nucleotide sequence selected from the group consisting of 5′-GAAA-3′, 5′-UUAG-3′, 5′-UGAAAA-3′, 5′-UUGAAAAA-3′, 5′-UUCGAAAGAA-3′ (SEQ ID NO: 240), 5′-UUCAGAAAUGAA-3′ (SEQ ID NO: 241), 5′-UUCAUGAAAAUGAA-3′ (SEQ ID NO: 242), and 5′-UUCAUUGAAAAAUGAA-3′ (SEQ ID NO: 243).

### Claim 38 (depends on 30)

The vector system of claim 30, wherein the scaffold region comprises an engineered tracrRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 251 to 296 and/or
an engineered crRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 297 to 304.

### Claim 39 (depends on 21)

The vector system of claim 21, wherein the first or second guide RNA comprises a scaffold region sequence of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 313 to 350.

### Claim 40 (depends on 21)

The vector system of claim 21, wherein the Cas12f1 molecule comprises an amino acid sequence having at least 70% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 360 to 364 and SEQ ID NOs: 370 to 377.

### Claim 41 (depends on 21)

The vector system of claim 21, wherein the vector further comprises a promoter or enhancer.

### Claim 42 (depends on 41)

The vector system of claim 41, wherein the promoter is U6 promoter, EFS promoter, EF1-αpromoter, H1 promoter, 7SK promoter, CMV promoter, LTR promoter, Ad MLP promoter, HSV promoter, SV40 promoter, CBA promoter, or RSV promoter.

### Claim 43 (depends on 21)

The vector system of claim 21, wherein the vector is selected from the group consisting of a retrovirus vector, a lentivirus vector, an adenovirus vector, an adeno-associated virus vector, a vaccinia virus vector, a poxvirus vector, a herpes simplex virus vector, and a phagemid vector.

### Claim 44 (depends on 21)

The vector system of claim 21, wherein the vector is selected from the group consisting of plasmid, naked DNA, DNA complex, mRNA (transcript), and amplicon.

### Claim 45 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A recombinant virus produced by the vector system of any one of claims 21 to 44.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A composition comprising the system of any one of claims 1 to 20, the vector system of any one of claims 21 to 44, or the recombinant virus of claim 45.

### Claim 47 (depends on 46)

The composition of claim 46, wherein the composition is a pharmaceutical composition.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for inducing deletion of a segment comprising exon 13 in a USH2A gene in a cell, comprising bringing, into contact with the cell, the system of any one of claims 1 to 20, the vector system of any one of claims 21 to 44, or the recombinant virus of claim 45.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for treating a subject having a disease associated with a mutation in exon 13 of the USH2A gene, comprising bringing, into contact with the subject, the system of any one of claims 1 to 20, the vector system of any one of claims 21 to 44, or the recombinant virus of claim 45.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for modifying a gene of a cell, comprising bringing, into contact with the cell, the system of any one of claims 1 to 20, the vector system of any one of claims 21 to 44, or the recombinant virus of claim 45.

### Claim 51 (depends on 48, 49, 50)

The method of any one of claims 48 to 50, wherein the recombinant virus is an adeno-associated virus (AAV).

### Claim 52 (depends on 48, 50)

The method of claim 48 or 50, wherein the cell is a stem cell, or a cell from the eye or inner ear of a mammal.

### Claim 53 (depends on 48, 50)

The method of claim 48 or 50, wherein the cell is derived from a subject having Usher syndrome.

### Claim 54 (depends on 48, 50)

The method of claim 48 or 50, wherein the bringing-into-contact occurs ex vivo or in vivo.

### Claim 55 (depends on 48, 50)

A stem cell genetically modified by the method of claim 48 or 50.

### Claim 56 (depends on 55)

The stem cell of claim 55, wherein the stem cell is for treating type 2A Usher syndrome.

### Claim 57

A guide RNA, comprising a spacer region, which comprises a guide sequence capable of hybridizing to a target sequence in a USH2A (Usherin) gene, and a scaffold region, wherein the guide sequence comprises (i) a sequence of contiguous 15 to 22 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 397 to 445, or a sequence that is different by 5 or fewer nucleotides from the contiguous nucleotide sequence, wherein thymine (T) in the contiguous nucleotide sequence is substituted with uracil (U), and/or (ii) a sequence of contiguous 15 to 20 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 446 to 475, or a sequence that is different by 5 or fewer nucleotides in the contiguous nucleotide sequence, wherein thymine (T) in the contiguous nucleotide sequence is substituted with uracil (U).

### Claim 58 (depends on 57)

The guide RNA of claim 57, wherein the guide sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 80 to 128 and SEQ ID NOs: 159 to 164, and/or
the guide sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 129 to 158 and SEQ ID NOs: 165 to 174.

### Claim 59 (depends on 57)

The guide RNA of claim 57, wherein the guide RNA comprises a U-rich tail sequence linked to the 3′ end of the guide sequence, in which the U-rich tail is represented by 5′-(UmV)nUo-3′, wherein V is each independently A, C, or G; m and o are integers between 1 to 20; and n is an integer between 0 to 5.

### Claim 60 (depends on 57)

The guide RNA of claim 57, wherein the scaffold region comprises a nucleotide sequence having at least 50% sequence identity to a scaffold region of a wild-type Cas12f1 guide RNA sequence, which sequentially comprises, from the 5′-end, a first stem-loop region, a second stem-loop region, a third stem-loop region, a fourth stem-loop region and a tracrRNA-crRNA complementarity region, and comprises at least one modification selected from the group consisting of the following (1) to (4) with respect to the wild-type Cas12f1 guide RNA sequence:
(1) deletion of at least a part of the first stem-loop region;
(2) deletion of at least a part of the second stem-loop region;
(3) deletion of at least a part of the tracrRNA-crRNA complementarity region; and
(4) replacement of one or more uracil (U) residues with A, G, or C in three or more consecutive U residues when the consecutive U residues are present in the tracrRNA-crRNA complementarity region.

### Claim 61 (depends on 60)

The guide RNA of claim 60, wherein the wild-type Cas12f1 guide RNA comprises tracrRNA comprising the nucleotide sequence of SEQ ID NO: 175 and crRNA comprising the nucleotide sequence of SEQ ID NO: 176.

### Claim 62 (depends on 60)

The guide RNA of claim 60, wherein the scaffold region comprises a sequence having at least 80% sequence identity to a sequence represented by Formula (I):
in Formula (I),
Xa comprises the nucleotide sequence of SEQ ID NO: 178 or a nucleotide sequence having the sequence of SEQ ID NO: 178 from which 1 to 20 nucleotides are deleted,
Xb1 comprises the nucleotide sequence of SEQ ID NO: 189 or a nucleotide sequence having the sequence of SEQ ID NO: 189 from which 1 to 13 nucleotides are deleted,
Xb2 comprises the nucleotide sequence of SEQ ID NO: 193 or a nucleotide sequence having the sequence of SEQ ID NO: 193 from which 1 to 14 nucleotides are deleted,
Xc1 comprises the nucleotide sequence of SEQ ID NO: 203 or a nucleotide sequence having the sequence of SEQ ID NO: 203 from which 1 to 28 nucleotides are deleted,
Xc2 comprises the nucleotide sequence of SEQ ID NO: 222 or a nucleotide sequence having the sequence of SEQ ID NO: 222 from which 1 to 27 nucleotides are deleted, and
Lk is a polynucleotide linker of 2 to 20 nucleotides in length or absent.

### Claim 63 (depends on 62)

The guide RNA of claim 62, wherein in a case where three or more consecutive uracil (U) residues are present in the Xc1 sequence, the Xc1 sequence comprises a modification in which at least one U residue thereof is replaced with A, G or C.

### Claim 64 (depends on 62)

The guide RNA of claim 62, wherein the deletion in the nucleotide sequence of Xa, the deletion in the nucleotide sequences of Xb1 and Xb2, and/or the deletion in the nucleotide sequences of Xc1 and Xc2 comprises deletion of one or more pairs of complementary nucleotides.

### Claim 65 (depends on 62)

The guide RNA of claim 62, wherein the sequence 5′-Xb1UUAGXb2-3 in Formula (I) is selected from the group consisting of SEQ ID NOs: 198 to 202 and 5′-UUAG-3′.

### Claim 66 (depends on 62)

The guide RNA of claim 62, wherein the sequence 5′-Xc1-Lk-Xc2-3 in Formula (I) is selected from the group consisting of SEQ ID NOs: 244 to 250 and 5′-Lk-3′.

### Claim 67 (depends on 62)

The guide RNA of claim 62, wherein the scaffold region comprises an engineered tracrRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 251 to 296 and/or
an engineered crRNA consisting of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 297 to 304.

### Claim 68 (depends on 57)

The guide RNA of claim 57, wherein the guide RNA is a single guide RNA.

### Claim 69 (depends on 57)

The guide RNA of claim 57, wherein the guide RNA comprises a scaffold region sequence of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 313 to 350.

### Claim 70 (depends on 57)

The guide RNA of claim 57, wherein the guide RNA comprises a scaffold region sequence of a nucleotide sequence selected from the group consisting of SEQ ID NOs: 315 to 317.

### Claim 71 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A nucleic acid molecule encoding the guide RNA of any one of claims 57 to 70.

### Claim 72 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A composition comprising at least one guide RNA of any one of claims 57 to 70.

### Claim 73 (depends on 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

A composition comprising at least one guide RNA of any one of claims 57 to 70 and an endonuclease comprising a Cas12f1 molecule.

### Claim 74 (depends on 72, 73)

The composition of claim 72 or 73, wherein the composition comprises two or more guide RNAs, of which (i) at least one guide RNA comprises a sequence of contiguous 15 to 22 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 397 to 445, or a sequence that is different by 5 or fewer nucleotides from the contiguous nucleotide sequence, and (ii) at least one other guide RNA comprises a sequence of contiguous 15 to 20 nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 446 to 475, or a sequence that is different by 5 or fewer nucleotides from the contiguous nucleotide sequence.
